SCHEDULE: Heron Therapeutics: Adage Capital Management Reports 0% Ownership

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has filed a Schedule 13G amendment indicating zero beneficial ownership of Heron Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Adage Capital Management, L.P. (ACM), Robert Atchinson, and Phillip Gross have filed an amendment to their Schedule 13G filing.
• The filing, dated March 31, 2026, indicates that the reporting persons collectively beneficially own 0.00 shares of Heron Therapeutics, Inc. common stock.
• This represents 0% of the class of securities.
• The reporting persons are investment managers and individuals associated with the management of these investment entities.
• The address for the reporting persons' business office is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it indicates a complete divestment of shares by a previously significant holder, suggesting a lack of confidence or a strategic shift away from Heron Therapeutics.

Negatives

• The reporting persons have zero beneficial ownership of Heron Therapeutics, Inc. common stock, indicating no current investment position.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding future performance or strategy.

Management Comments

• The filing certifies that the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. A filing indicating 0% ownership suggests a divestment or a change in reporting status, which can be significant for understanding institutional holdings.

Stakeholder Impact

• Shareholders may note the absence of Adage Capital Management as a significant holder, which could influence market perception of institutional support.

Key Dates

Keywords

Heron Therapeutics, Schedule 13G, Adage Capital Management, SEC Filing, Ownership, Investment Management, Securities